PaperFactors associated with bacteraemia in febrile, granulocytopenic cancer patients
References (30)
An approach to the management of infants with impaired haemostasis
Clin Haematol
(1991)Basic principles of ROC analysis
Semin Nucl Med
(1978)Approach to treatment of the febrile cancer patient with low-risk neutropenia
Hematol/Oncol Clin North Am
(1993)- et al.
Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital
J Pediatr
(1992) - et al.
Empiric antibiotic therapy for suspected infections in granulocytopenic cancer patients. A comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin
Am J Med
(1982) Infectious complications in the child with cancer. I, Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient
J Pediatr
(1981)- et al.
Improved prognosis for granulocytopenic patients with gram-negative bacteremia
Am J Med
(1980) - et al.
Norfloxacin for prevention of bacterial infections in granulocytopenic patients
Am J Med
(1987) - et al.
Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis
Am J Med
(1988) - et al.
Pefloxacin and vancomycin vs. gentamicin, colistin sulphate and vancomycin for prevention of infections in granulocytopenic patients: a randomised double blind study
Eur J Cancer
(1991)
Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia
N Engl J Med
Three antibiotic regimens in the treatment of infections in febrile granulocytopenic patients with cancer
J Infect Dis
Empiric antimicrobial therapy for febrile, granulocytopenic cancer patients: lessons from 4 EORTC trials
Eur J Cancer Clin Oncol
Vanomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
J Infect Dis
Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients
J Clin Oncol
Cited by (117)
Platelets in Host Defense: Experimental and Clinical Insights
2019, Trends in ImmunologyCitation Excerpt :Together, these types of findings have supported the concept that platelets play a role in host defense against pathogens in humans. Along the same lines, another study focusing on neutropenic cancer patients with leukemia or solid tumors identified thrombocytopenia as an independent risk factor for hospital-acquired bacteremia in a multivariate analysis [99]. Moreover, a prospective study evaluating predictive factors for invasive bacterial infection among children with (hematological and solid) cancer, fever, and neutropenia identified a platelet count below 50 000/μl as a risk predictor for invasive bacterial infection [100].
The role of platelets in antimicrobial host defense
2019, PlateletsThe rise of ampicillin-resistant Enterococcus faecium high-risk clones as a frequent intestinal colonizer in oncohaematological neutropenic patients on levofloxacin prophylaxis: A risk for bacteraemia?
2016, Clinical Microbiology and InfectionCitation Excerpt :In neutropenic oncohaematological patients, chemotherapy-induced neutropenia is of concern because its duration and severity are narrowly related to the development of infection. Moreover, bacteraemia constitutes the most frequent cause of infection-related mortality, which occurs in 20–40% of febrile neutropenic patients [1]. To reduce the risk of infection, different antibiotic-based prophylaxis regimens, such as co-trimoxazole, cephalosporins or fluoroquinolones, have been assayed [2,3].
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia
2013, Journal of Infection and ChemotherapyAntimicrobial Host Defense
2013, PlateletsAntimicrobial Host Defense
2012, Platelets, Third Edition